Multiple Myeloma Genomics Initiative Sequences Myeloma Genomes
Myeloma Research Foundation (MMRF) and Multiple Myeloma Research Consortium (MMRC) announced the MMRC Multiple Myeloma Genomics Initiative has completed the sequencing of the first multiple myeloma whole genomes. This is the first time multiple myeloma whole genomes have been sequenced and will be used to identify key targets for new treatments.
“Groundbreaking data from the MMRC Multiple Myeloma Genomics Initiative will play an important role in developing better treatment options for individuals who derive little benefit from existing therapies and may ultimately help provide multiple myeloma patients with the most appropriate treatment for his or her disease,” Louise M. Perkins, PhD, Chief Scientific Officer of the MMRF. “Furthermore, knowledge from this effort could also benefit patients with other types of cancer.”
The critical task of analyzing the data from the project, conducted in collaboration with the Broad Institute of MIT and Harvard, is now underway, and additional genomes are also being sequenced. A portal to facilitate data access is being constructed and these first complete multiple myeloma genomes will be made available to researchers everywhere within the next several months.
“Through its extraordinary generosity and vision, the MMRF is enabling the important work of whole genome sequencing for multiple myeloma, and making the data publicly accessible,” said Todd R. Golub, MD, Director of the Broad Institute’s Cancer Program and co-principal investigator of the MMRC Multiple Myeloma Genomics Initiative. “This is a remarkable beginning.”
The Multiple Myeloma Genomics Initiative is a comprehensive genomic analysis program designed to rapidly accelerate progress made against multiple myeloma by significantly improving the understanding of the biology of the disease.
Spearheaded by the MMRF and conducted in collaboration with the Broad Institute and the Translational Genomics Research Institute (TGen), the Multiple Myeloma Genomics Initiative utilizes tissue samples from the MMRC Tissue Bank to advance cutting-edge research and discovery efforts that span the spectrum of genomic science. Data from the Initiative are placed into the public domain in near-real time via the Multiple Myeloma Genomics Portal, the world's only myeloma-specific repository of genomic data, and can be accessed at www.myelomagenomics.org.
The Multiple Myeloma Genomics Initiative has also just completed two other high resolution genomics profiling studies performed at TGen on the full Reference Collection of 250 patient's multiple myeloma tumor tissue. Jeffrey Trent, PhD, President and Scientific Director of TGen and co-principal investigator on the Multiple Myeloma Genomics Initiative, said, “The Multiple Myeloma Genomics Initiative has created an unprecedented opportunity to examine an extraordinary breadth of genomic information to pinpoint the most important genes and cellular processes driving the disease. Such a remarkable dataset exists for very few other cancers; it will no doubt pave the way toward personalized medicine for multiple myeloma patients.”
“Groundbreaking data from the MMRC Multiple Myeloma Genomics Initiative will play an important role in developing better treatment options for individuals who derive little benefit from existing therapies and may ultimately help provide multiple myeloma patients with the most appropriate treatment for his or her disease,” Louise M. Perkins, PhD, Chief Scientific Officer of the MMRF. “Furthermore, knowledge from this effort could also benefit patients with other types of cancer.”
The critical task of analyzing the data from the project, conducted in collaboration with the Broad Institute of MIT and Harvard, is now underway, and additional genomes are also being sequenced. A portal to facilitate data access is being constructed and these first complete multiple myeloma genomes will be made available to researchers everywhere within the next several months.
“Through its extraordinary generosity and vision, the MMRF is enabling the important work of whole genome sequencing for multiple myeloma, and making the data publicly accessible,” said Todd R. Golub, MD, Director of the Broad Institute’s Cancer Program and co-principal investigator of the MMRC Multiple Myeloma Genomics Initiative. “This is a remarkable beginning.”
The Multiple Myeloma Genomics Initiative is a comprehensive genomic analysis program designed to rapidly accelerate progress made against multiple myeloma by significantly improving the understanding of the biology of the disease.
Spearheaded by the MMRF and conducted in collaboration with the Broad Institute and the Translational Genomics Research Institute (TGen), the Multiple Myeloma Genomics Initiative utilizes tissue samples from the MMRC Tissue Bank to advance cutting-edge research and discovery efforts that span the spectrum of genomic science. Data from the Initiative are placed into the public domain in near-real time via the Multiple Myeloma Genomics Portal, the world's only myeloma-specific repository of genomic data, and can be accessed at www.myelomagenomics.org.
The Multiple Myeloma Genomics Initiative has also just completed two other high resolution genomics profiling studies performed at TGen on the full Reference Collection of 250 patient's multiple myeloma tumor tissue. Jeffrey Trent, PhD, President and Scientific Director of TGen and co-principal investigator on the Multiple Myeloma Genomics Initiative, said, “The Multiple Myeloma Genomics Initiative has created an unprecedented opportunity to examine an extraordinary breadth of genomic information to pinpoint the most important genes and cellular processes driving the disease. Such a remarkable dataset exists for very few other cancers; it will no doubt pave the way toward personalized medicine for multiple myeloma patients.”
posted by gwg at 4:41 PM
0 Comments:
Post a Comment
<< Home